We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+12.11%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$177M
AUM Growth
+$177M
Cap. Flow
+$20.1M
Cap. Flow %
11.35%
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$3.68M
2
FULC icon
Fulcrum Therapeutics
FULC
+$3.52M
3
CERS icon
Cerus
CERS
+$3.5M
4
ARVN icon
Arvinas
ARVN
+$3.29M
5
NXTC icon
NextCure
NXTC
+$3.18M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.49M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.79M
3
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.54M
4
RNLX
Renalytix plc American Depositary Shares
RNLX
+$2.3M
5
CRIS icon
Curis
CRIS
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Financials 5.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARCT icon
76
Arcturus Therapeutics
ARCT
$168M
$297K 0.17%
+6,208
New +$278K
XENE icon
77
Xenon Pharmaceuticals
XENE
$6.2B
$297K 0.17%
+19,432
New +$338K
AFMD
78
DELISTED
Affimed
AFMD
$292K 0.17%
4,718
-15,501
-77% -$1.02M
IVVD icon
79
Invivyd
IVVD
$171M
$211K 0.12%
+5,000
New +$186K
RCOR.WS
80
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$42K 0.02%
+104,828
New +$81.8K
GYRE icon
81
Gyre Therapeutics
GYRE
$648M
$41K 0.02%
+1,333
New +$43.9K
MSACW
82
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$35K 0.02%
49,990
– –
AKRO
83
DELISTED
Akero Therapeutics
AKRO
– –
-33,028
Closed -$819
ALDX icon
84
Aldeyra Therapeutics
ALDX
$96.5M
– –
-192,345
Closed -$2.18K
APLS
85
DELISTED
Apellis Pharmaceuticals
APLS
– –
-7,009
Closed -$443
ARDX icon
86
Ardelyx
ARDX
$1.25B
– –
-99,237
Closed -$752
ASND icon
87
Ascendis Pharma A/S
ASND
$16.5B
– –
-5,599
Closed -$737
ATXS
88
DELISTED
Astria Therapeutics
ATXS
– –
-31,463
Closed -$398
CGEM icon
89
Cullinan Oncology
CGEM
$1.08B
– –
-75,732
Closed -$1.95K
DCTH icon
90
Delcath Systems
DCTH
$416M
– –
-99,189
Closed -$1.25K
ETNB
91
DELISTED
89bio
ETNB
– –
-28,032
Closed -$524
ETON icon
92
Eton Pharmaceutcials
ETON
$1.34B
– –
-18,691
Closed -$115
KALV
93
DELISTED
KalVista Pharmaceuticals
KALV
– –
-14,882
Closed -$357
MCRB icon
94
CALL
Seres Therapeutics
MCRB
$46.3M
– –
-6,135
Closed -$2.93K
MDGL icon
95
Madrigal Pharmaceuticals
MDGL
$11.4B
– –
-2,480
Closed -$242
MGNX icon
96
MacroGenics
MGNX
$240M
– –
-176,915
Closed -$4.75K
MRSN
97
DELISTED
Mersana Therapeutics
MRSN
– –
-5,005
Closed -$1.7K
PHGE icon
98
BiomX
PHGE
$2.04M
– –
-75
Closed -$78
QURE icon
99
uniQure
QURE
$2.93B
– –
-9,346
Closed -$288
RCKT icon
100
Rocket Pharmaceuticals
RCKT
$351M
– –
-10,293
Closed -$456
1 2 3
4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, up 78,789% from $224K the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Silverarc Capital Management deployed $20.1M of net new capital in Q3 2021, opening 21 new positions and adding to 27 existing holdings. Its largest new stake was Fulcrum Therapeutics: 185,691 shares worth $5.24M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $5.49M trimmed.

  • Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
  • Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
  • Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
  • Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8K.
  • Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
  • Silverarc Capital Management's portfolio value rose 78,789% quarter-over-quarter to $177M.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.